Current Status of Haploidentical Stem Cell Transplantation for Leukemia

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2009 Jan 2

PMID 19117511

Citations 21

Authors

Xiao-Jun Huang

Affiliations

Soon will be listed here.

Abstract

Haploidentical hematopoietic stem cell transplantation has made tremendous progress over the past 20 years and has become a feasible option for leukemia patients without a HLA identical sibling donor. The early complications of severe graft-versus-host disease (GVHD), graft failure and delayed engraftment, as well as disease recurrence have limited the use of this approach. Newer strategies have been applied and overcome some of the problems, including the use of T-cell depleted graft, "mega" dose of stem cells, intensive post-transplant immunosuppression and manipulation of the graft. These have decreased the transplant related mortality and GVHD associated with haploidentical transplantation, however, the major problems of disease relapse and infection, which related to late immune reconstitution, limit the development of haploidentical HSCT. Future challenges remain in improving post-transplant immune reconstitution and finding the best approach to reduce the incidence and severity of GVHD, while preserving graft-versus-leukemia effect to prevent the recurrence of underlying malignancy.

Citing Articles

HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study.

Yang T, Xie Z, Xu Z, Tu B, Lu H, Huang H Emerg Microbes Infect. 2024; 13(1):2364744.

PMID: 38935839 PMC: 11212569. DOI: 10.1080/22221751.2024.2364744.

Cytomegalovirus infection is associated with rapid NK differentiation and reduced incidence of relapse in HLA matched sibling donor transplant patients.

Han T, Xie J, Zhao X, Lv M, Chang Y, Xu L Clin Exp Immunol. 2022; 210(3):283-294.

PMID: 36383237 PMC: 9985159. DOI: 10.1093/cei/uxac099.

Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.

Wen B, Zhang X, Chen S, Fan J, Yang S, Cai Y Hematol Oncol. 2022; 40(4):777-786.

PMID: 35554955 PMC: 9790607. DOI: 10.1002/hon.3017.

Advances in preclinical hematopoietic stem cell models and possible implications for improving therapeutic transplantation.

Fraint E, Ulloa B, Norberto M, Potts K, Bowman T Stem Cells Transl Med. 2020; 10(3):337-345.

PMID: 33058566 PMC: 7900582. DOI: 10.1002/sctm.20-0294.

Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience.

Lv W, Qu H, Wu M, Fan Z, Huang F, Xu N Cancer Med. 2019; 8(15):6549-6558.

PMID: 31502764 PMC: 6825994. DOI: 10.1002/cam4.2539.

References

Passweg J, Stern M, Koehl U, Uharek L, Tichelli A . Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. 2005; 35(7):637-43. DOI: 10.1038/sj.bmt.1704810. View

Dey B, Spitzer T . Current status of haploidentical stem cell transplantation. Br J Haematol. 2006; 135(4):423-37. DOI: 10.1111/j.1365-2141.2006.06300.x. View

Amrolia P, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A . Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006; 108(6):1797-808. PMC: 1895537. DOI: 10.1182/blood-2006-02-001909. View

Aversa F, Reisner Y, Martelli M . The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis. 2007; 40(1):8-12. DOI: 10.1016/j.bcmd.2007.07.004. View

Bignon J, Gagne K . KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005; 17(5):553-9. DOI: 10.1016/j.coi.2005.07.014. View

Solomon S, Mielke S, Savani B, Montero A, Wisch L, Childs R . Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005; 106(3):1123-9. PMC: 1895160. DOI: 10.1182/blood-2005-01-0393. View

Huang X, Liu D, Liu K, Xu L, Chen Y, Wang Y . Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol. 2008; 28(3):276-83. DOI: 10.1007/s10875-007-9166-z. View

Lang P, Bader P, Schumm M, Feuchtinger T, Einsele H, Fuhrer M . Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol. 2003; 124(1):72-9. DOI: 10.1046/j.1365-2141.2003.04747.x. View

Kato S, Yabe H, Yasui M, Kawa K, Yoshida T, Watanabe A . Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant. 2001; 26(12):1281-90. DOI: 10.1038/sj.bmt.1702707. View

10.

Liu D, Huang X, Liu K, Xu L, Chen H, Han W . Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant. 2008; 14(4):469-77. DOI: 10.1016/j.bbmt.2008.02.007. View

11.

Bethge W, Faul C, Bornhauser M, Stuhler G, Beelen D, Lang P . Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2007; 40(1):13-9. DOI: 10.1016/j.bcmd.2007.07.001. View

12.

Jun H, Jun C, Yu Z . A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica. 2005; 90(5):715-6. View

13.

Dazzi F, Szydlo R, Cross N, Craddock C, Kaeda J, Kanfer E . Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000; 96(8):2712-6. View

14.

Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli M . Haploidentical stem cell transplantation in leukemia. Blood Rev. 2001; 15(3):111-9. DOI: 10.1054/blre.2001.0157. View

15.

Henslee-Downey P, Abhyankar S, Parrish R, Pati A, Godder K, Neglia W . Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997; 89(10):3864-72. View

16.

Hossain M, Roback J, Wang F, Waller E . Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol. 2008; 180(10):6892-902. DOI: 10.4049/jimmunol.180.10.6892. View

17.

Liu D, Tammik C, Zou J, Ernberg I, Masucci M, Ringden O . Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clin Transplant. 2004; 18(5):518-24. DOI: 10.1111/j.1399-0012.2004.00198.x. View

18.

Huang X, Liu D, Xu L, Chen H, Han W, Liu K . Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia. 2005; 20(2):365-8. DOI: 10.1038/sj.leu.2403995. View

19.

Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H . Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003; 31(1):39-44. DOI: 10.1038/sj.bmt.1703779. View

20.

Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007; 92(3):414-7. DOI: 10.3324/haematol.10570. View